TABLE 1.

Clinical characteristics of patients included in the TRG and RECIST1.1 groups.

Factors	TRG		RECIST1.1
	Grades 0, 1, 2 (n = 120)	Grades 3 (n = 72)	CR + PR (n = 116)	SD + PD (n = 76)
Age	55.63 ± 9.02	55.82 ± 9.21	55.84 ± 9.02	55.47 ± 9.19
Sex
Female	25 (20.8)	7 (9.7)	22 (20.0)	10 (13.2)
Male	95 (79.2)	65 (90.3)	94 (80.0)	66 (86.8)
Tumor location
Diffuse type	10 (8.3)	5 (6.9)	9 (7.8)	6 (7.9)
Lower	41 (34.2)	27 (37.5)	41 (35.3)	27 (35.5)
Middle	37 (30.8)	26 (36.1)	34 (29.3)	29 (38.2)
Upper	32 (26.7)	14 (19.5)	32 (27.6)	14 (18.4)
Differentiation (before NACT)
Poorly	75 (62.5)	64 (88.9)	71 (61.2)	68 (89.5)
Moderate and well	45 (37.5)	8 (11.1)	45 (38.8)	8 (10.5)
cT stage
2	17 (14.2)	4 (5.6)	17 (14.7)	4 (5.3)
3	83 (69.2)	40 (55.6)	84 (72.4)	39 (51.3)
4	20 (16.6)	28 (38.9)	15 (12.9)	33 (43.4)
cN stage
Negative	25 (20.8)	17 (23.6)	27 (23.3)	15 (19.7)
Positive	95 (79.2)	55 (72.4)	89 (76.7)	61 (80.3)
cTNM
III	45 (37.5)	35 (48.6)	40 (34.5)	40 (52.6)
IIa	37 (30.8)	16 (22.2)	40 (34.5)	13 (17.1)
IIb	38 (31.7)	21 (29.2)	36 (31.0)	23 (30.3)
BMI
18.5–24	74 (61.7)	50 (69.4)	75 (64.7)	49 (64.5)
<18.5 or >24	46 (38.3)	22 (30.6)	41 (35.3)	27 (35.5)
Tumor diameter
<5 cm	85 (70.8)	32 (44.4)	82 (70.7)	35 (46.1)
≥5 cm	35 (29.2)	40 (55.6)	34 (29.3)	41 (53.9)
Chemotherapy cycles
2–3	67 (55.8)	50 (69.4)	68 (58.6)	49 (64.5)
4	53 (44.2)	22 (30.6)	48 (41.4)	27 (35.5)
ASA
1 and 2	94 (78.3)	61 (84.7)	91 (78.4)	64 (84.2)
3	26 (21.7)	11 (15.3)	25 (21.6)	12 (15.8)

Abbreviations: ASA, American Society of Anesthesiologists Score; BMI, body mass index.

Note: Tumor location classified as upper 1/3, middle 1/3, lower 1/3, diffuse TNM staging according to the American Cancer Consortium (AJCC).